Source – Eversana
Eversana and Amazon Web Services (AWS) have formed an alliance to accelerate the adoption of generative artificial intelligence (AI) in the pharmaceutical industry. Eversana, a provider of commercialization services to pharma and life sciences clients, will collaborate with AWS to bring generative AI to the sector, a technology that uses algorithms like ChatGPT to create new content.
The potential of generative AI is widely recognized, and many believe it will revolutionize how organizations operate. According to a recent poll, 86% of IT leaders believe it will drive efficiency and innovation in the near future. However, the pharma industry requires tailored solutions to meet its highly technical demands.
“We believe we are at an inflection point in the life sciences industry with the rising influence of AI to transform capabilities and reimagine everything from customer experiences and omnichannel engagement to software development and operating models. Companies that find the optimal balance of human and AI-powered services will leap ahead in every industry, and pharma is no different. Together with AWS, our goal is to bring AI across the life sciences industry or ‘pharmatize it,’ shaping the future of digital transformation, driving value for our clients and making a remarkable difference in the lives of patients.”
– Jim Lang, CEO, EVERSANA
Eversana and AWS plan to deliver customized tools that will reimagine various aspects of the industry, from customer experiences and omnichannel engagement to software development and operating models. Jim Lang, Eversana’s CEO, emphasized the importance of this partnership in achieving these goals.
The initial focus of the collaboration will be on three key areas. Firstly, the development of tools for medical and regulatory review processes, aiming to streamline and automate the time-consuming manual operations currently involved. Secondly, they aim to leverage AI for field and patient assistance, using chatbots to automate mundane tasks and improve patient engagement. Lastly, they plan to develop AI-driven content generation for disease and product education, enabling more effective interactions with patients and healthcare professionals.
In this partnership, Eversana will bring its digital and AI expertise, which will be combined with Amazon Bedrock, AWS’ service for building and scaling generative AI applications. The Bedrock platform, launched earlier this year, offers in-house foundation models (FMs) – a type of AI trained on large datasets adaptable to various tasks and operations – along with a marketplace of pre-trained models from third-party companies.
This alliance takes advantage of the strengths of both companies, enabling the pharmaceutical industry to leverage cutting-edge generative AI technology without the need for large investments in data centers. Similar marketplace approaches have been taken by tech giants Google and Microsoft with their respective Google Cloud and Azure platforms, allowing partner companies to train AI tools on the platforms without the need for extensive infrastructure investments.
